cytotoxic T cell

(redirected from Cytotoxic T-lymphocytes)
Also found in: Dictionary, Thesaurus, Encyclopedia.

cytotoxic T cell

cytotoxic T cell

See CD8 cell.

cytotoxic T cell

A CD8+ T lymphocyte that can destroy microorganisms directly through the release of perforin and proteolytic enzymes. These cells are particularly important in the defense against viruses, rejection of allografts, and, possibly, new malignant cells. Synonym: CD8 cell; cytotoxic cel; killer T cell
See also: cell
References in periodicals archive ?
The research, published in the September 1, 2002 issue of Cancer Research, shows that RNA encoding the protein component of telomerase (TERT RNA), when introduced into dendritic cells (DCs), is effective in priming telomerase-specific cytotoxic T-lymphocytes (CTLs) to target and destroy malignant tumors.
The Company has exclusive rights to a patent, issued to the Fred Hutchinson Cancer Research Center in October 1998, related to a process for rapidly expanding cytotoxic T-lymphocytes in culture to millions or billions of cells that retain their ability to recognize specific disease-related antigens.
Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the Company is developing drug candidates under two distinct approaches: the immune suppression program targets inflammatory diseases and reperfusion injury through the use of cell adhesion blockers that prevent the excessive migration of white blood cells into surrounding tissue, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers by stimulating production of antigen- specific cytotoxic T-lymphocytes by the immune system.
Utilizing Cytel's advanced understanding of the immune system's operation both in disease and in health, the Company is developing drug candidates under two distinct approaches: the immune suppression program targets inflammatory diseases and reperfusion injury through use of cell adhesion blockers that prevent the excessive migration of white blood cells into surrounding tissue, and the immune stimulation program is directed to the development of therapeutic vaccines to treat infectious diseases and cancers by stimulating production of antigen-specific cytotoxic T-lymphocytes by the immune system.
The principal technology to emerge from the joint venture is the Theradigm immune stimulation technology, providing a novel therapeutic approach to selectively stimulate the human immune system to produce a disease-specific response from white blood cells, or cytotoxic T-lymphocytes (CTLs).
The company is focused on developing recombinant-based vaccines and the use of adjuvants and carrier systems to enhance the number and activity of cytotoxic T-lymphocytes (CTLs) to combat cancer in patients with minimal tumor burden.
RLI has obtained an exclusive license from the University of Virginia to innovative technology which is used to identify antigenic peptides that stimulate the immune system toward producing a disease-specific response from a class of white blood cells known as cytotoxic T-lymphocytes (CTLs).